Newly diagnosed patients treated with drugs alone more likely to progress
SAN DIEGO -- Despite the success of novel targeted agents in newly diagnosed multiple myeloma, an upfront stem cell transplant remains the best treatment choice, a researcher said here.
In a large randomized clinical trial, European investigators compared two forms of intensification therapy: high-dose melphalan (HMD) plus an autologous stem cell transplant or standard-dose bortezomib-melphalan-prednisone (VMP), according to Michele Cavo, MD, PhD, of the Bologna University School of Medicine in Italy.
After a median follow-up of nearly 32 months, the median progression-free survival (PFS) had not been reached for those getting a transplant but was 42.5 months for those getting the VMP regimen, Cavo reported at the American Society of Hematology (ASH) annual meeting.
Jump HERE for more
Easy Pineapple Upside Down Cake
5 days ago